AR015946A1 - Formulacion farmaceutica que comprende bifosfonatos, proceso para su preparacion, uso de la formulacion para la fabricacion de un medicamento, metodo parala inhibicion de la reabsorcion osea, y metodo para el tratamiento y prevencion de osteoporosis - Google Patents

Formulacion farmaceutica que comprende bifosfonatos, proceso para su preparacion, uso de la formulacion para la fabricacion de un medicamento, metodo parala inhibicion de la reabsorcion osea, y metodo para el tratamiento y prevencion de osteoporosis

Info

Publication number
AR015946A1
AR015946A1 ARP980104956A ARP980104956A AR015946A1 AR 015946 A1 AR015946 A1 AR 015946A1 AR P980104956 A ARP980104956 A AR P980104956A AR P980104956 A ARP980104956 A AR P980104956A AR 015946 A1 AR015946 A1 AR 015946A1
Authority
AR
Argentina
Prior art keywords
formulation
osteoporosis
prevention
treatment
reabsortion
Prior art date
Application number
ARP980104956A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR015946A1 publication Critical patent/AR015946A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Las formulaciones farmacéuticas comprenden por lo menos un bisfosfonato y un agente mejorador de la absorcion que consiste esencialmente de un glicérido decadena medio o una mezcla de glicéridos de cadena media. Dichas formulaciones farmacéuticas sonutiles para la inhibicion de la reabsorcion osea y para eltratamiento y prevencion de la osteoporosis.
ARP980104956A 1997-10-10 1998-10-05 Formulacion farmaceutica que comprende bifosfonatos, proceso para su preparacion, uso de la formulacion para la fabricacion de un medicamento, metodo parala inhibicion de la reabsorcion osea, y metodo para el tratamiento y prevencion de osteoporosis AR015946A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9703691A SE9703691D0 (sv) 1997-10-10 1997-10-10 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
AR015946A1 true AR015946A1 (es) 2001-05-30

Family

ID=20408561

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980104956A AR015946A1 (es) 1997-10-10 1998-10-05 Formulacion farmaceutica que comprende bifosfonatos, proceso para su preparacion, uso de la formulacion para la fabricacion de un medicamento, metodo parala inhibicion de la reabsorcion osea, y metodo para el tratamiento y prevencion de osteoporosis

Country Status (14)

Country Link
US (1) US6372728B1 (es)
EP (2) EP1310259A3 (es)
JP (1) JP2001519398A (es)
AR (1) AR015946A1 (es)
AT (1) ATE240107T1 (es)
AU (1) AU9469198A (es)
DE (1) DE69814656T2 (es)
DK (1) DK1021194T3 (es)
ES (1) ES2200378T3 (es)
PT (1) PT1021194E (es)
SA (1) SA98190775A (es)
SE (1) SE9703691D0 (es)
WO (1) WO1999018972A1 (es)
ZA (1) ZA988886B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2321864A1 (en) * 1998-12-25 2000-07-06 Toray Industries, Inc. Interleukin-6 production inhibitor
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
SE9901272D0 (sv) * 1999-04-09 1999-04-09 Astra Ab New improved formulation
RU2288722C2 (ru) * 2000-06-20 2006-12-10 Новартис Аг Способ введения бисфосфонатов
NZ523086A (en) 2000-06-20 2007-07-27 Novartis Ag Method of administering bisphosphonates
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
JP4381805B2 (ja) * 2001-07-02 2009-12-09 メリオン リサーチ スリー リミテッド 生物活性材料の送達
JP4546704B2 (ja) * 2002-02-14 2010-09-15 救急薬品工業株式会社 経皮投与製剤
KR100998856B1 (ko) 2002-02-14 2010-12-08 규큐 야쿠힝 고교 가부시키가이샤 경피투여제제
KR20120065435A (ko) 2002-05-10 2012-06-20 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
ITMI20032175A1 (it) * 2003-11-11 2005-05-12 Tiberio Bruzzese Formulazioni farmaceutiche di bisfosfonati destinate
US20050182028A1 (en) * 2004-02-13 2005-08-18 Chen Chih-Ming J. Pharmaceutical formulation for oral delivery of bisphosphates
KR20080083068A (ko) * 2004-05-24 2008-09-12 더 프록터 앤드 갬블 캄파니 킬레이팅제를 함유하는 비스포스포네이트의 고형의 장용 경구 투여 형태
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
US7358361B2 (en) * 2004-10-08 2008-04-15 The Board Of Trustees Of The University Of Illinois Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
CN101227892B (zh) * 2005-04-08 2013-06-05 舌交付有限公司 口腔给药系统
US7473684B2 (en) * 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
CA2646334A1 (en) * 2006-03-17 2007-09-27 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
MX2008012678A (es) * 2006-04-07 2008-12-17 Merrion Res Iii Ltd Forma de dosis oral solida que contiene un mejorador.
WO2007132714A1 (ja) * 2006-05-16 2007-11-22 The Nisshin Oillio Group, Ltd. 骨密度増加剤
CA2654566A1 (en) * 2006-06-09 2007-12-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
GB0616794D0 (en) 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
US8974801B2 (en) * 2006-12-21 2015-03-10 Amphastar Pharmaceuticals Inc. Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
KR20110007242A (ko) * 2008-05-07 2011-01-21 메리온 리서치 Ⅲ 리미티드 펩티드 조성물 및 그의 제조 방법
US20100215743A1 (en) * 2009-02-25 2010-08-26 Leonard Thomas W Composition and drug delivery of bisphosphonates
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
CN103476419A (zh) 2011-01-07 2013-12-25 梅里翁第三研究有限公司 口服投药的含铁药物组合物
ES2975708T3 (es) 2015-01-29 2024-07-12 Novo Nordisk As Comprimidos que comprenden agonista del GLP-1 y recubrimiento entérico
CN105267145B (zh) * 2015-11-01 2019-06-21 袁旭东 双膦酸盐的自乳化配方和相关剂型

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL175882C (nl) * 1977-03-28 Procter & Gamble Farmaceutisch preparaat, dat een verbinding met ontstekingtegengaande werking bevat.
GB8618259D0 (en) * 1986-07-25 1986-09-03 Leo Pharm Prod Ltd Pharmaceutical compositions
MX21452A (es) * 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
DE69023844T2 (de) * 1989-09-06 1996-06-20 Merck & Co Inc Acyloxymethylester der Bisphonsäuren als Knochenresorptions-Inhibitoren.
SE9003100D0 (sv) 1990-09-28 1990-09-28 Kabivitrum Ab Lipid formulation system
US5391743A (en) * 1992-05-29 1995-02-21 Procter & Gamble Pharmaceuticals, Inc. Quaternary nitrogen-containing phosphonate compounds, pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism and methods of treating and preventing dental calculus and plaque
EP0684834A4 (en) 1993-02-17 1996-09-25 Smithkline Beecham Corp MICROEMULSIONS CONTAINING THERAPEUTIC PEPTIDES.
JP3411690B2 (ja) * 1994-09-21 2003-06-03 帝人株式会社 局所投与用アレンドロン酸ナトリウム製剤
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon

Also Published As

Publication number Publication date
ZA988886B (en) 1999-04-12
JP2001519398A (ja) 2001-10-23
EP1310259A2 (en) 2003-05-14
EP1021194B1 (en) 2003-05-14
WO1999018972A1 (en) 1999-04-22
SE9703691D0 (sv) 1997-10-10
DK1021194T3 (da) 2003-09-01
ATE240107T1 (de) 2003-05-15
DE69814656D1 (de) 2003-06-18
US6372728B1 (en) 2002-04-16
EP1310259A3 (en) 2003-05-21
ES2200378T3 (es) 2004-03-01
PT1021194E (pt) 2003-09-30
AU9469198A (en) 1999-05-03
EP1021194A1 (en) 2000-07-26
SA98190775A (ar) 2005-12-03
DE69814656T2 (de) 2004-03-25

Similar Documents

Publication Publication Date Title
AR015946A1 (es) Formulacion farmaceutica que comprende bifosfonatos, proceso para su preparacion, uso de la formulacion para la fabricacion de un medicamento, metodo parala inhibicion de la reabsorcion osea, y metodo para el tratamiento y prevencion de osteoporosis
NZ514478A (en) A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate
PA8484301A1 (es) Formulaciones farmaceuticas de liberacion controlada
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
CO5150154A1 (es) Composicion de sustrato y metodo para usarlo para el secuestro de irritantes de la piel
WO2002041837A3 (en) Treatment of mucositis
AR012671A1 (es) Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos
PT1183014E (pt) Composicoes farmaceuticas orais de libertacao controlada e de dissimulacao de sabor
BR0112094A (pt) Produtos de confeitaria contendo ingredientes ativos
ES2181017T3 (es) Composicion farmaceutica que contiene una sustancia promotora de osteogenesis y un polietilenglicol.
DE69501419D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von Osteoporose enthaltend Xanthohumol
ATE395071T1 (de) Pharmazeutische zubereitungen zur angiogenese- therapie
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
GT199800177A (es) Combinacion eficaz para el tratamiento de la impotencia .
WO1997004788A3 (en) Use of calendula glycosides for the treatment of psoriasis
AR028448A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
ES2172171T3 (es) Medicamento, que contiene yohimbina y arginina, para el tratamiento de disfunciones erectiles.
DE60202590D1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
NO994395L (no) Stabilt, fast preparat som inneholder vitamin D3 og trikalsiumfosfat
PA8490701A1 (es) Composiciones extruidas livianas que contiene un portador ceramico liviano extruible, metodos de uso de las mismas y procesos para su preparacion
AR047480A1 (es) Composicion para la prevencion y/o tratamiento de enfermedades metabolicas oseas; proceso de preparacion y uso de esta composicion
BR0013416A (pt) Droga, uso de uma droga selecionada do grupo que consiste de pelo menos um bisfosfonato, e, método para tratamento de um osso fraturado
AR003001A1 (es) Composicion farmaceutica estimuladora de la osteogenesis.
CL2004001291A1 (es) Composicion farmaceutica que comprende compuestos carbociclicos y heterociclicos; y su uso para el tratamiento o profilaxis de la infeccion por influenza.
PL368040A1 (en) Substituted 4-aminocyclohexanol derivatives

Legal Events

Date Code Title Description
FA Abandonment or withdrawal